福州公孙策公关咨询有限公司合伙人詹军豪在接受《证券日报》记者采访时表示："药明康德临床后期 和商业化项目增长带来的产能效率不断提升，以及公司在2024年出售持有的药明合联生物技术有限公司 部分股权及处置交割部分业务带来的大额投资收益，提升了公司整体业绩。公司独特的'一体化、端到 端'CRDMO业务模式成效显著，化学业务增长突出，尤其是TIDES业务（寡核苷酸和多肽）增长迅猛， 为公司业绩提供了有力支撑。" 4月28日晚间，无锡药明康德新药开发股份有限公司（以下简称"药明康德"）发布2025年一季度报告。 报告期内，公司实现营业收入96.55亿元，同比增长20.96%；实现归属于上市公司股东的净利润36.72亿 元，同比增长89.06%。 数据显示，公司第一季度实现营业收入96.55亿元，其中持续经营业务收入93.9亿元，同比增长23.1%。 按营业收入贡献前三名业务来看，化学业务第一季度实现收入73.91亿元，同比增长32.87%；测试业务 第一季度实现收入12.92亿元，同比下降4.04%；生物学业务第一季度实现收入6.08亿元，同比增长 8.25%。 分地区来看，今年第一季度，药明康德来自美国客户收入63 ...

此外，报告期内公司经营活动产生的现金流量净额同比增长41.57%，主要系报告期内公司持续的利润 增长带来了良好的现金流入，确保了经营现金流的稳定与健康。 当季公司毛利率为42.26%，保持在近年来的高位。 一季报还显示，截至2025年3月末，公司持续经营业务在手订单523.3亿元，同比增长 47.1%。报告期内 来自美国客户收入63.8亿元，同比增长28.4%；来自欧洲客户收入13.0亿元，同比增长26.2%；来自中国 客户收入15.3 亿元，同比下降1.3%；来自其他地区客户收入4.5亿元，同比增长3.0%。 （文章来源：新华财经） 新华财经上海4月28日电（林郑宏）A股CRO（医药外包）行业龙头药明康德4月28日发布2025年一季 报，显示当季实现营业收入96.55亿元，同比增长20.96%；归属于上市公司股东的净利润36.72亿元，同 比增长89.06%；扣非净利润23.29亿元，同比增长14.50%。 公司表示，报告期内公司净利大幅增长主要系公司在保持营业收入增长的同时，不断优化生产工艺和经 营效率，以及临床后期和商业化项目增长带来的产能效率不断提升，提高了整体盈利能力；同时，公司 出售持有的药明合联 ...

药明康德仍预计2025年持续经营业务收入将实现10%-15%的双位数增长。 从药明康德目前披露的订单情况来看，截至2025年3月底，公司持续经营业务在手订单523.3亿元，同比 增长47.1%；TIDES在手订单同比增长105.5%。 前期，截至2024年12月底，公司持续经营业务在手订单493.1亿元，也是同比增长47%。 如果扣除这些影响，药明康德经调整non-IFRS（非国际财务报告准则）归母净利润26.78亿元，同比增 长40%。 作为药明康德近年来业绩新增长点之一，TIDES业务（寡核苷酸和多肽）今年一季度收入达到22.4亿 元，同比增长187.6%。 美东时间4月2日，美方宣布对所有贸易伙伴征收"对等关税"。这对于美国市场收入占比达到66%的药明 康的来说，这将对公司未来业绩产生哪些影响？ 4月10日上午，药明康德在上海交易所举办的2024年业绩说明会上表示，关税对公司肯定会有影响，影 响多少现在还很不明朗。 4月28日晚间，药明康德（603259.SH、02359.HK）交出了一份业绩亮丽的一季报，公司的营业收入以 及归属于上市公司股东的净利润均恢复到两位数增长。 具体看，今年一季度，公司实现营 ...

一、增持 1、德昌股份：拟定增募资不超过15.24亿元，用于泰国厂区年产500万台家电产品建设项目、年产180万 台智能生活家居家电用品项目、年产500万台高性能无刷直流电机建设项目、越南厂区年产300万台小家 电产品建设项目、补充流动资金项目。 4、威孚高科：与博世中国签署《新时期战略合作协议》，双方将继续推进在传感器领域的业务合作， 并拓展至潜在的其它智能产品；双方将共同拓展相关产品在人工智能和具身机器人等领域的工业应用； 双方将继续探索在PEM电解水制氢领域的互利合作机会。 二、回购、增持 1、人福医药：招商生物拟增持0.5%-1%公司股份。 2、海鸥股份：拟6000万元-1.2亿元回购公司股份。 3、华联控股：拟变更8011.53万股回购股份用途并注销。 4、禾丰股份：拟将回购专用证券账户中的695.66万股股份予以注销。 三、对外投资、日常经营 1、嘉泽新能：拟投资8.03亿元建设140MW风电项目。 2、宏和科技：拟投资约7.2亿元建设高性能玻纤纱产线建设项目。 3、新坐标：拟7700万元设立控股子公司，研发、生产和销售滚柱丝杠等。 四、业绩变动 1、友发集团：一季度净利润1.33亿元，同比增长9 ...

4月28日，药明康德今日收盘58.09元，上涨1.27%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到17.75倍，创17天以来新低，总市值1677.63亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均40.74倍，行业中值42.36倍，药明康德排 名第17位。 截至2025年一季报，共有383家机构持仓药明康德，其中基金378家、其他5家，合计持股数110978.81万 股，持股市值747.11亿元。 无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新 药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务。 最新一期业绩显示，2025年一季报，公司实现营业收入96.55亿元，同比20.96%；净利润36.72亿元，同 比89.06%，销售毛利率42.26%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)17药明康德17.7517.752.691677.63亿行业平均 40.7444.103.33146.85亿行业中值42.3641.212.3351.49亿1润达医疗-269.96178.652.3398.76亿2普瑞 ...

药明康德为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美 等地均设有运营基地。公司通过独特的CRDMO业务模式，不断降低研发门槛，助力客户提升研发效 率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和 临床试验研究等领域。 4月28日晚间，药明康德（603259）发布2025年一季报，报告期内，公司实现营业收入96.55亿元，同比 增长20.96%；归属于上市公司股东的净利润36.72亿元，同比增长89.06%；归属于上市公司股东的扣除 非经常性损益的净利润23.29亿元，同比增长14.50%。截至2025年3月底，公司持续经营业务在手订单 523.3亿元，同比增长47.1%。 一季度，公司化学业务实现收入人民币73.9亿元，同比增长32.9%。一季报显示，小分子药物发现 ("R"，Research)业务为下游持续引流。过去12个月，公司为客户成功合成并交付超过46万个新化合物， 同比增长6%。公司贯彻"跟随客户"和"跟随分子"战略，与全球客户建立了值得信赖的合作关系，为公 司CRDMO业务持续增长奠定坚实基础。2025年第一季度R到D ...

Financial Performance - The company's revenue for Q1 2025 reached ¥9,654,595,304.28, representing a 20.96% increase compared to ¥7,981,934,236.96 in the same period last year[6] - Net profit attributable to shareholders was ¥3,671,960,950.47, marking an 89.06% increase from ¥1,942,210,693.65 year-over-year[6] - Basic earnings per share rose to ¥1.29, a 92.54% increase from ¥0.67 in the previous year[6] - Total operating revenue for Q1 2025 reached ¥9,654,595,304.28, an increase of 21% compared to ¥7,981,934,236.96 in Q1 2024[21] - Net profit for Q1 2025 was ¥3,715,468,841.04, up 90% from ¥1,958,853,204.95 in Q1 2024[21] - Operating profit for Q1 2025 was ¥4,292,748,775.29, compared to ¥2,309,847,178.76 in Q1 2024, reflecting a growth of 86%[21] - The total comprehensive income for Q1 2025 was RMB 3,696.7 million, compared to RMB 1,745.1 million in Q1 2024, marking a 111.5% increase[29] - The company reported a gross profit of RMB 4,013.1 million for Q1 2025, compared to RMB 3,005.7 million in Q1 2024, reflecting a 33.4% increase[27] - The operating profit for Q1 2025 was RMB 4,158.9 million, significantly higher than RMB 2,324.9 million in Q1 2024, representing a 78.9% increase[27] Cash Flow and Investments - The net cash flow from operating activities was ¥3,195,429,861.72, up 41.57% from ¥2,257,117,807.86 in the same period last year[6] - The net cash flow from operating activities for Q1 2025 was RMB 3,195.4 million, compared to RMB 2,257.1 million in Q1 2024, reflecting a 41.5% increase[25] - The net cash flow from investing activities for Q1 2025 was RMB 2,199.8 million, a significant recovery from a negative RMB 854.4 million in Q1 2024[25] - The company reported a net cash inflow from investing activities of CNY 2,366.4 million in Q1 2025, compared to a net outflow of CNY 734.6 million in Q1 2024[33] Assets and Liabilities - The total assets at the end of the reporting period were ¥84,512,088,093.23, a 5.21% increase from ¥80,325,824,408.75 at the end of the previous year[6] - Total assets as of March 31, 2025, amounted to ¥84,512,088,093.23, an increase from ¥80,325,824,408.75 at the end of 2024[19] - Total liabilities increased to ¥21,733,326,335.92 from ¥21,240,210,773.18, indicating a rise of approximately 2.3%[19] - The total liabilities as of March 31, 2025, were CNY 21,733.3 million, slightly up from CNY 21,240.2 million as of December 31, 2024[31] - The total equity attributable to shareholders increased to ¥62,332,382,757.11 from ¥58,632,715,174.37, reflecting a growth of 6%[19] - The company’s total equity as of March 31, 2025, was CNY 62,778.8 million, an increase from CNY 59,085.6 million as of December 31, 2024[31] Business Segments and Growth - The company reported a significant increase in the chemical business revenue, which reached ¥739,097.03, up 32.87% from ¥556,262.85 in Q1 2024[9] - The chemical business generated revenue of RMB 7.39 billion, reflecting a year-on-year increase of 32.9%[10] - The small molecule D&M business reported revenue of RMB 3.85 billion, a year-on-year growth of 13.8%, with a total pipeline of 3,393 molecules as of the end of the reporting period[11] - TIDES business revenue surged to RMB 2.24 billion, marking a year-on-year increase of 187.6%, with backlog orders up 105.5%[11] - The testing business generated revenue of RMB 1.29 billion, with laboratory analysis and testing services revenue at RMB 880 million, down 4.9% year-on-year[14] - The clinical CRO and SMO business reported revenue of RMB 410 million, a year-on-year decline of 2.2%, while SMO revenue grew by 5.5%[14] - The biological business achieved revenue of RMB 610 million, reflecting an 8.2% year-on-year increase, with in vitro screening platform revenue up 28.9%[14] Operational Efficiency and Future Plans - The company continues to optimize production processes and operational efficiency, enhancing overall profitability through growth in late-stage clinical and commercialization projects[6] - The company plans to enhance its peptide solid-phase synthesis capacity, expecting the total volume of reactors to exceed 100,000L by the end of 2025[11] - The company successfully synthesized and delivered over 460,000 new compounds in the past 12 months, a 6% increase year-on-year[11] Market Position and Reputation - The company maintains a strong reputation in the global pharmaceutical R&D industry, driven by its integrated CRDMO business model[4] - As of March 2025, the company's backlog for continuing operations reached RMB 52.33 billion, a year-on-year increase of 47.1%[10]

Financial Performance - The company's operating revenue for Q1 2025 reached RMB 9.65 billion, representing a 20.96% increase compared to RMB 7.98 billion in the same period last year[14]. - Net profit attributable to shareholders was RMB 3.67 billion, up 89.06% from RMB 1.94 billion year-on-year[14]. - Basic earnings per share rose to RMB 1.29, a 92.54% increase from RMB 0.67 in the same period last year[14]. - The company reported a backlog of orders for ongoing operations amounting to RMB 52.33 billion, a year-on-year increase of 47.1%[24]. - The company reported a total comprehensive income of ¥3,833,942,277.47 for Q1 2025, compared to ¥1,745,131,836.43 in Q1 2024, an increase of approximately 119%[47]. Cash Flow and Assets - The net cash flow from operating activities increased by 41.57% to RMB 3.20 billion, compared to RMB 2.26 billion in the previous year[14]. - The company achieved a net cash flow from operating activities of RMB 4.16 billion, reflecting strong profit growth and stable cash inflow[22]. - Cash and cash equivalents increased to RMB 24.85 billion from RMB 18.32 billion, representing a significant rise of approximately 35.5%[39]. - The total assets at the end of the reporting period were RMB 84.51 billion, reflecting a 5.21% increase from RMB 80.33 billion at the end of the previous year[16]. - The total liabilities as of March 31, 2025, amounted to ¥21,733,326,335.92, slightly up from ¥21,240,210,773.18 as of December 31, 2024[41]. Business Segments and Growth - Revenue from the chemistry business (WuXi Chemistry) was RMB 73.9 billion, up 32.9% year-on-year, with over 460,000 new compounds synthesized in the past 12 months[24]. - The TIDES business (oligonucleotides and peptides) saw revenue growth of 187.6%, with a backlog increase of 105.5%[24]. - Revenue from the testing business (WuXi Testing) was RMB 12.9 billion, with a slight decline of 4.04% year-on-year due to market price factors[25]. - Revenue from the biology business (WuXi Biology) increased by 8.2%, supported by a strong pipeline and new customer acquisition[25]. - The company plans to expand its peptide production capacity, expecting the total volume of peptide solid-phase synthesis reactors to exceed 100,000L by the end of 2025[24]. Shareholder Information - The company reported a total of 243,477 common stock shareholders, with 243,419 being A-share holders and 58 H-share holders[35]. - The top ten shareholders collectively hold 56.4% of the shares, with HKSCC Nominees Limited being the largest shareholder at 13.40%[31]. - The company has a significant presence of foreign institutional investors, with multiple entities holding over 1% of the shares[31]. Research and Development - The company continues to enhance its CRDMO business model to improve research and development efficiency for clients[12]. - The company is committed to maintaining the highest international quality regulatory standards in its operations[12]. - Research and development expenses for Q1 2025 were ¥224,408,414.09, down from ¥306,402,572.33 in Q1 2024, a decrease of about 27%[45].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年4月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | | 佔有關事件前的現有已發 | | ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 ■ 注： 1、公司的前十大股东和前十大无限售条件股东一致。 3、HKSCC NOMINEES LIMITED 即香港中央结算（代理人）有限公司，其所持股份是代表多个客户持 有；香港中央结算有限公司为沪港通人民币普通股的名义持有人。 特此公告。 无锡药明康德新药开发股份有限公司（以下简称"公司"）于2025年3月17日召开第三届董事会第十七次 会议暨2024年年度董事会，审议通过《关于2025年以集中竞价交易方式回购公司A股股份的议案》。具 体内容详见2025年3月18日公司于上海证券交易所网站及指定媒体披露的《关于2025年以集中竞价交易 方式回购A股股份的预案》（公告编号：2025-017）。本次回购股份方案尚待将于2025年4月29日召开 的公司2024年年度股东大会审议。 无锡药明康德新药开发股份有限公司董事会 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将2024年年度股东大会的股权登记日（即2025年4月24日）登记 ...